Epilepsy is a chronic, neurological disorder, which
has been around for 3000 years, and causes unprovoked, recurrent seizures
with impacts ranging from social stigma, isolation, and injury including sudden death.
People with epilepsy - globally
People with Epilepsy in the US
New cases diagnosed annually in the US
Seizure detection solutions to help patients improve quality of life
Annual medical expenditures on Epilepsy in the US
Existing solutions are simply insufficient
Our seizure detection software software algorithm uses oculometric data (i.e, eye movements) to reliably detect a seizure. By employing machine learning capabilities, our software will also be able to predict when a seizure will occur. We expect our software to easily interface and/or integrate with other eye tracking systems (eg. smart glasses) and therapeutic devices (eg. neuromodulation).
It is expected that 100% of all seizures will be detected in an ambulatory setting
Potentially, there are several opportunities to help revolutionize epilepsy care:
We recently completed a 30 patient proof-of-concept study which resulted in robust seizure detection of the subtlest seizure type, absence seizures.
We are planning to create eye-tracking wearables to be used in a clinical study within the next year....so stay tuned!
Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland
Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.
Leads the Eysz cognitive research team. Practicing neuropsychology for over 12 years primarily in the Bay Area. She is also the head Neuropsychologist in the Epilepsy department at UCSF Benioff Children’s Hospital Oakland
Experienced clinical device development and go-to-market strategist with 15+ years of global medical device and partnership experience. Currently develops and manages our partner ecosystem.
Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center. He had research awards from the Klingenstein Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles and 4 books. He was named 1996-2016 in Best Doctors in America. He received the Ambassador Award from the International League Against Epilepsy, the 2005 AES Service Award and the 2006 Annual Clinical Research Award.
Dr. Blumenfeld's clinical and research work focuses on epilepsy, cognition and brain imaging. He directs Yale's Clinical Neuroscience Imaging Center (CNIC), a new multi-disciplinary core facility for innovative study and treatment of brain disorders. Teaching activities include a textbook titled Neuroanatomy Through Clinical Cases, Sinauer Assoc., Publ. 2002, 2010.
Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology, up until October 2016, when purchased by Google. He continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets. He now serves as the President of Parallel Rules consulting firm.
Steve brings 30+ years of leadership and strategy experience in the Medical Device industry. He has held a variety of leadership roles in various cross functional areas. Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis. Under his leadership, the company has grown in revenues, remained debt-free, and has expanded into new markets.
Accurately detecting seizures outside of a hospital- based setting is like
trying to diagnose a fever without a thermometer. We just don’t have the tools to do it well.